Dean J. Larry Jameson of the Perelman School of Medicine discusses Penn’s new research partnership with Norvatis.
Perelman School of Medicine
PHILADELPHIA — In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.
PHILADELPHIA — The National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI) awarded $18.5 million to establish the Personalized NSAID Therapeutics Consortium (PENTACON), an international group of scientists led by Garret A. FitzGerald, MD, FRS, director of the Institute for Translational Medicine and Therapeutics at the Perelman School of Medicine, University of Pennsylvania.
Penn Researcher Calls for Additional Strategies to Properly Weigh Benefits, Risks of Prescribing Painkillers
A new risk management plan from the U.S. Food and Drug Administration to help clinicians properly prescribe drugs with addiction potential aims to help reduce the growing epidemic of opioid abuse in the United States.
Media Contact:Evan Lerner | firstname.lastname@example.org | 215-573-6604August 1, 2012
PHILADELPHIA — Two University of Pennsylvania professors have been named winners of Presidential Early Career Awards for Scientists and Engineers.